Clinical Diagnosis

Adam S. Wenick, MD, PhD, discussed myopia interventions across the lifespan at EyeCon 2024, covering treatments, complications, and prevention strategies.

Adam S. Wenick, MD, PhD, chaired a symposium on geographic atrophy (GA) at EyeCon 2024, focusing on the diagnosis, monitoring, and FDA-approved treatments for GA. The session with Leonard Messner, OD, FAAO, also included case presentations that highlighted key factors for clinicians to consider when selecting appropriate treatment options.

Laura M. Periman, MD, shares her passion for dry eye disease, discussing her discovery of the Alpenglow Sign in Demodex blepharitis and her insights on research and education for clinicians. Periman will join the EyeCon 2024 faculty as Honorary Chair.

David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular degeneration at the Retina Society 57th Annual Scientific Meeting in Lisbon, Portugal.

Push to identify biomarkers for earlier diagnosis, new therapeutic targets.

Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.

Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry at EyeCon.

Early diagnosis of NMOSD is key to preventing disability, improving survival.

Researchers train deep learning model on OCT scans to ID patients eligible for GA trials.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness.

Optimizing corneal neurotization outcomes with cryopreserved amniotic membrane.

VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Researchers examined data of more than 200,000 people, some at an early stage of the disease and some without age-related eyesight issues

According to the company, it will finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

Low birth weight, blood transfusion, necrotising enterocolitis, bronchopulmonary dysplasia and antenatal steroid and surfactant therapies are among the factors that affect the development of ROP.

Investigators put forth a list of considerations for surgeons ahead of lens removal in pediatric patients

According to a study, the research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD

Authors pointed out that understanding this link may aid with genetic counseling or surveillance of affected individuals, potentially contributing to improved management and outcomes.

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

Schocket has been serving as Interim chair since July, 2022, and during that time has worked to establish best practices for the department, strengthening its academic programs and improving its financial viability.

Understanding how the intricate networks of blood vessels in the eye and brain are formed ultimately could inspire new treatments for conditions like diabetic retinopathy and stroke.

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.

McDonnell stays focused on helping the next generation of ophthalmologists launch their careers in academics.

Office transitions to a portable vision diagnostic and patient engagement system.

According to ophthalmologists at the Colorado University School of Medicine, discussing mental well-being is a key part of effective treatment and improving care for patients.

The campaign will encourage, educate and empower the public to include vision and eye health as a part of their healthcare by asking them to share how eye care services and exams improved their vision and their daily lives.

Researchers at Massachusetts Eye and Ear led a phase 1/2 trial, which included 14 participants, that found the experimental treatment was safe and efficacious.

A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.

Physicians should consider the roles of verbal and ocular anesthesia.